May 6, 2024 4:50pm

Earnings this week: Ionis Pharmaceuticals (IONS), Agenus (AGEN) on Tuesday, 5/7, Editas Medicine (EDIT), Vericel (VCEL), Lenz Therapeutics (LENZ) on Wednesday, 5/8; BioLife Solutions (BLFS), blue bird bio (BLUE), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO) on Thursday, 5/9

Let’s not forget about volatility.

News: Cellectis (CLLS +$0.36) clearance from the French Ministry of Economy and satisfaction of AstraZeneca (AZN) completing the additional equity investment of $140M, as previously announced by CLLS on November 1 and 15, 2023

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter about – facts in evidence! 

 

Monday: The Dow closed UP+156.59 points or +0.46%, the S&P closed UP +52.95 points or +1.03% while the Nasdaq closed UP +192.92 points or +1.19%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes advanced Monday, building on the previous session’s strong gains, as traders lifted Fed rate cut expectations.

 

RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441   

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Advance/Decline (A/D) Line:

  • Monday’s advance/decline line at the open was positive with 217 incliner, 16 decliners and 2 flats; ending with a positive close of 17 incliners, 15 decliners and 3 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 4 positive closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was up +0.05% and the XBI was up +0.67%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.01 point or -0.07% at 13.48

 

Monday’s Closing Down (10 of xx):

  • Alnylam Pharmaceuticals (ALNY -$1.11 after Friday’s +$2.02),
  • Blueprint Medicine (BPMC -$0.94 after Friday’s +$0.19
  • Vericel (VCEL-$0.89 after Friday’s -$0.05
  • Sage Therapeutics (SAGE -$0.69 after Friday’s +$0.84
  • Beam Therapeutics (BEAM -$0.35 after Friday’s +$0.41
  • Lenz Therapeutics (LENZ -$0.28),
  • MiMedx (MDXG -$0.24 after Friday’s -$0.13),
  • Prime Medicine (PRME -$0.19 after Friday’s -$0.02),
  • Agenus (AGEN -$0.12 after Friday’s +$0.55)
  • AxoGen (AXGN -$0.12 after Friday’s -$0.09)

Flat (3):

  • Compass Therapeutics (CMPX)
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Verve Therapeutics (VERV)

Monday’s Closing Up (10 of 17):

  • CRISPR Therapeutics (CRSP +$1.17 after Friday’s +$0.82
  • Mesoblast (MESO +$0.51),
  • Cellectis SA (CLLS +$0.36 after Friday’s $0.00),
  • Ionis Pharmaceuticals (IONS +$0.31 after Friday’s -$1.12),
  • Ultragenyx Pharmaceuticals (RARE +$0.26 after Friday’s -$0.45
  • Adverum Biogeotechnology’s (ADVM +$0.23)
  • Generation Bio (GBIO +$0.18)
  • Fate Therapeutics (FATE +$0.16 after Friday’s -$0.03),
  • Voyager Therapeutics (VYGR +$0.13 after Friday’s +$0.28),
  • Intellia Therapeutics (NTLA +$0.12 after Friday’s +$0.33

 

Q2/24 – May

  • (5/6) Monday closed positive with 17 incliners, 15 decliners and 3 flats
  • Friday closed positive with 22 incliners, 12 decliners and 1 flat
  • Thursday closed positive with 25 incliners, 9 decliners and 1 flat
  • Wednesday closed positive with 28 incliners, 6 decliners and 1 flat

 

The BOTTOM LINE: this week will see the continuance of Q1 financial performance of cell and gene therapy companies that will shed light on share value.

  • Equites are currently trading "rotating fair value" while trading recently higher so far this month of May after a rotten and depreciating April.
  • There is also a "lop-sided risk to the downside." He identifies Middle East tensions, Fed uncertainty over interest rates, and economic data as potential risks that could impact share value’s performance moving forward.

Earnings: https://www.regmedinvestors.com/articles/11628

  • ALNY:  Q1 loss, tops revenue estimate
  • AXGN: Q1 loss, lags revenue estimates
  • BPMC: Q1 net incomes, surpasses revenue estimates

Earnings whispers:

  • BioLife Solutions (BLFS) to deliver a year-over-year increase in earnings on lower revenues. BLFS is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +18.8%. Revenues are expected to be $29.3 million, down 22.3% from the year-ago quarter.
  • Adverum Biotechnologies (ADVM) to deliver a year-over-year increase in earnings on lower revenues
  • Beam Therapeutics Inc. (BEAM) is expected to deliver a year-over-year decline in earnings on lower revenues
  • Ionis Pharmaceuticals (IONS) to post quarterly loss of $1.10 per share in its upcoming report, which indicates a year-over-year decline of 26.4%. Revenues are expected to be $131.51 million, up 0.4% from the year-ago quarter.
  • CRISPR Therapeutics (CRSP) Revenues in the to-be-reported quarter are likely to have been driven by collaboration revenues from Vertex. The Zacks Consensus Estimate for total revenues stands at $8.31 million.
  • From Zacks investment Research

The top three (3) performing in the session:  

  • Monday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Cellectis SA (CLLS)

The worst three (3) in the session:

  • Monday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Vericel (VCEL

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.